rhTNFR-Fc
PreclinicalSmall molecule
rhTNFR-Fc is one of 43 small molecule programs targeting Necrosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in Necrosis
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zoloft
VViatris Specialty LLC
Approved
Botox
AbbVieApproved
Adenocard
AstellasPhase 3
Crestor
AstraZenecaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhTNFR-Fc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLihua Duan